Faricimab in Neovascular Age-Related Macular Degeneration: Primary Results From the Phase 3 TENAYA and LUCERNE Trials (AMD)
This activity is provided by Med Learning Group.
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Copyright © 2019Med Learning Group. Built by Divigner. All Rights Reserved.